Save the date for this ILD Conference in 2014

We are pleased to announce the conference  "Fibrosing interstitial lung diseases of idiopathic and exogenous origin -Phenotype approach" which will be held in the beautiful city of Prague (Czech Republique), June 19-21, 2014. View our flyer.  

WASOG 2013 Conference

We are pleased to invite you to participate in the 6th International WASOG Conference on Diffuse Parenchymal Lung Diseases, Paris, June 6-7, 2013. The conference will focus on idiopathic pulmonary fibrosis, sarcoidosis and other interstitial lung diseases. The conference will be held in La Sorbonne, one of the most prestigious centers of intelligence and culture, of science and of the arts in France. For more information visit the conference website: www.wasog2013.com.

• Registration fee increases from April 1st, 2013! 
• Deadline for registration: June 5th, 2013.
• Abstract submission deadline EXTENDED again: April 15th 2013!!

Follow WASOG on LinkedIn, Twitter and via our e-Newsletter

In addition to this website WASOG will keep you informed using several media. Updates include WASOG news, conference updates and other relevant information we would like to share with you. We therefore invitite you to subscribe to our e-Newsletter and/or follow @wasog on Twitter. You may also join our group on LinkedIn to expand your professional network and participate in discussions.

Sarcoidosis and other ild around the world

To inform you about sarcoidosis and other ild in different countries we ask(ed) colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site. Read more

WASOGBAL 2014 Announced!

The 3rd joint WASOGBAL conference (10th WASOG Meeting and the 12th International Conference on BAL) will be held in Izmir, Turky, October 2014. View our flyer. Any news will be posted here on the website and communicated through the e-newsletter and twitter.
 

---

New Literature

Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis, by Kron et al. Implantable cardiac defibrillator (ICD) implantation is a class IIA recommendation for patients with cardiac sarcoidosis (CS). However, little is known about the efficacy and safety of ICDs in this population. A multicentre retrospective data review evaluated the efficacy and safety of ICDs in patients with CS. Data were collected on 235 patients from 13 institutions, 64.7% male with mean age 55.6 ± 11.1. Over a mean follow-up of 4.2 ± 4.0 years, 85 of 234 (36.2%) patients received an appropriate ICD therapy (shocks and/or anti-tachycardia pacing) and 67 of 226 (29.7%) received an appropriate shock. Patients with CS and ICDs are at high risk for ventricular arrhythmias. This population also has high rates of inappropriate shocks and device complications. Read more ►

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis, by Denning et al. Chronic pulmonary aspergillosis (CPA) may complicate pulmonary sarcoidosis. The global burden of sarcoidosis and the burden of CPA complicating sarcoidosis was re-estimated. We searched the literature and reference lists of retrieved papers to identify all published sarcoidosis incidence and prevalence data. We estimated the frequency of CPA from 11 papers relating to >3,000 patients with sarcoidosis to derive CPA patient numbers. We applied an annual attrition rate of 15% (range 10–25%) to estimate the global burden of CPA. As CPA responds to long-term antifungal therapy, which may prevent life-threatening haemoptysis, screening periodically for CPA in those with pulmonary sarcoidosis may be important, especially in patients requiring corticosteroid therapy. Read more ►

Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis, by Mostard RL, et al. Assessing inflammatory activity is useful in the management of persistent symptomatic sarcoidosis patients. (18)F-FDG PET (PET) has been shown to be a sensitive technique to assess inflammatory activity in sarcoidosis. The aim of this study was to evaluate whether the severity of pulmonary involvement is associated with PET activity in persistent symptomatic sarcoidosis patients (n=95). The severity of the pulmonary involvement, assessed by HRCT features and lung function parameters, appeared to be associated with PET activity in sarcoidosis. The majority of patients with fibrotic changes demonstrated inflammatory activity at pulmonary and extrathoracic sites. Read more ►

Safety and efficacy of ARA290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double blind, pilot study by Heij et al. ARA290, a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, anti‐inflammation, and healing, reduces allodynia in preclinical neuropathy models. We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in 22 patients with sarcoidosis. ARA 290 appears to be safe in patients with sarcoidosis and to reduce neuropathic symptoms. Read more ►

Find all our selected literure on our key papers.